NASDAQ$VXRT
Vaxart Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced business update and financial results for the third quarter of 2024.
Vaxart reported its Q3 2024 financial results, highlighting the ongoing progress with the COVID-19 vaccine program, including the near completion of enrollment for the sentinel cohort in the Phase 2b study. The company also received feedback from the FDA on its norovirus program and is evaluating next steps.
- Sentinel cohort dosing was successfully initiated, keeping the company on track with BARDA contract milestones.
- Enrollment of the sentinel cohort is expected to be completed in November 2024.
- Constructive feedback was received from the FDA on the norovirus program, and next steps are being evaluated.
- Potentially more potent norovirus GI.1 and GII.4 constructs were created by the scientific team.
Headline financials
Revenue & EPS history
Vaxart · Revenue · Quarterly
$4.93M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.4%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
37%
23 / 62 earnings
Positive
+22.7%
Q1 2024
Best reaction
-23.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | -8.8% | -19.5% | |
| Q4 2025 | -13.0% | -14.9% | -14.9% | |
| Q3 2025 | +11.6% | +5.4% | +0.0% | |
| Q1 2025 | -0.7% | +19.0% | +66.7% | |
| Q4 2024 | -9.1% | -19.3% | -40.4% | |
| Q3 2024 | -12.8% | -15.3% | -18.1% | |
| Q2 2024 | -2.7% | +0.0% | +48.3% | |
| Q1 2024 | +22.7% | +35.2% | +7.0% | |
| Q4 2023 | -4.4% | +2.7% | -19.5% | |
| Q3 2023 | +8.4% | +12.3% | +12.3% | |
| Q2 2023 | +1.3% | -3.9% | +9.2% | |
| Q1 2023 | +0.0% | +0.0% | +44.8% | |
| Q4 2022 | +0.0% | -10.1% | -16.5% | |
| Q3 2022 | -11.9% | +16.1% | -20.3% | |
| Q2 2022 | +3.4% | +1.2% | -31.1% | |
| Q1 2022 | -9.6% | -6.2% | +5.1% | |
| Q4 2021 | +18.9% | +12.8% | +13.9% | |
| Q3 2021 | -8.0% | -6.7% | -12.9% | |
| Q2 2021 | +5.4% | +11.6% | +4.9% | |
| Q1 2021 | -18.7% | -33.2% | -31.7% | |
| Q4 2020 | -2.6% | -2.7% | -18.4% | |
| Q3 2020 | +10.0% | +23.0% | +61.4% | |
| Q2 2020 | -4.9% | +11.3% | -49.0% | |
| Q1 2020 | +1.1% | -2.1% | -20.7% | |
| Q4 2019 | -23.1% | -27.4% | -15.0% | |
| Q3 2019 | -2.9% | -11.4% | -8.6% | |
| Q2 2019 | +21.1% | +17.5% | +22.8% | |
| Q1 2019 | +8.5% | +9.9% | -8.5% | |
| Q4 2018 | -9.5% | -12.2% | -25.3% | |
| Q3 2018 | -15.8% | -12.1% | +0.7% | |
| Q2 2018 | +0.6% | -1.0% | +0.3% | |
| Q1 2018 | -5.3% | -1.8% | +1.8% | |
| Q4 2017 | +4.8% | +0.0% | +9.5% | |
| Q3 2017 | -2.0% | +0.0% | -6.0% | |
| Q2 2017 | -1.7% | -1.7% | -46.6% | |
| Q1 2017 | -8.3% | -4.1% | -33.2% | |
| Q4 2016 | +0.0% | +11.3% | +12.0% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | -15.2% | — | — | |
| Q1 2016 | +7.6% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -3.1% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q3 2014 | -6.3% | — | — | |
| Q2 2014 | +0.2% | — | — | |
| Q1 2014 | +1.5% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +2.6% | — | — | |
| Q1 2013 | +0.6% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | +1.1% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -1.0% | — | — | |
| Q2 2010 | -5.2% | — | — | |
| Q2 2011 | -5.2% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +0.2% | — | — | |
| Q1 2010 | -7.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro